Introduction

Umbilical cord blood transplantation (UCBT) is a suitable alternative for patients with acute leukemia (AL) in need of an allograft and who lack an HLA-matched donor. Single-institution and registry studies have shown that, in both children and adults with AL, the outcome of UCBT is comparable to that of matched unrelated donor. At the same time, these studies have highlighted some limitations of UCBT, such as increased early mortality and delayed recovery of both hematopoietic and immune compartment, which hamper a more widespread adoption of this approach.

Areas covered

In this review, we will analyze the current results of UCBT in children and adults with AL, including comparisons with other hematopoietic stem cell sources and transplant strategies. We will also discuss important factors to be considered when selecting UCB units, as well as future strategies to further improve the outcome of UCBT recipients.

Expert opinion

The utilization of UCBT for the treatment of AL patients has decreased in recent years. However, recent clinical data suggesting that UCBT might offer better results in patients with minimal residual disease, as well as innovative strategies to facilitate engraftment, reduce transplant-related mortality, and optimize anti-leukemic activity, may pave the way toward a second youth for use of UCB cells.

中文翻译：

---

脐血移植治疗急性白血病。

介绍

对于需要同种异体移植且缺乏HLA匹配供体的急性白血病（AL）患者，脐带血移植（UCBT）是合适的替代选择。单一机构和注册研究表明，在患有AL的儿童和成人中，UCBT的结果与匹配的无关亲戚的结果相当。同时，这些研究突出了UCBT的一些局限性，例如早期死亡率增加以及造血和免疫区室的恢复延迟，这阻碍了该方法的更广泛采用。

覆盖区域

在本综述中，我们将分析儿童和成人AL患者UCBT的当前结果，包括与其他造血干细胞来源和移植策略的比较。我们还将讨论选择UCB单位时要考虑的重要因素，以及进一步改善UCBT接收者结果的未来策略。

专家意见

近年来，UCBT用于治疗AL患者的应用有所减少。但是，最近的临床数据表明，UCBT可能在残留疾病最少的患者中提供更好的结果，以及促进植入，降低与移植相关的死亡率并优化抗白血病活性的创新策略，可能会为第二个年轻人铺平道路。使用UCB细胞。